1. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs;Strong;Food Drug Law J.,1999
2. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition;Kraushaar;Food Drug J.,2000
3. The enantiomer debate: current status and future directions 16;Hindmarch;Hum. Psychopharmacol. Clin. Exp.,2001
4. The cost benefit ratio of enantiomeric drugs;Pifferi;Eur. J. Drug Metab. Pharmacokinet.,1995
5. Chiral drugs: the FDA perspective on manufacturing and control;De Camp;J. Pharmaceut. Biomed. Anal.,1993